Recent News

• 02.11.2026 - Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
• 02.04.2026 - Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
• 01.09.2026 - Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
• 01.08.2026 - Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
• 01.05.2026 - Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Recent Filings

• 02.11.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.11.2026 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 02.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.03.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.14.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.13.2026 - 144 Report of proposed sale of securities
• 01.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.09.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]